This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chang, S.-H. Articles by Hla, T. Search for Related Content PubMed PubMed Citation Articles by Chang, S.-H. Articles by Hla, T.

The Prostaglandin E₂ Receptor EP2 Is Required for Cyclooxygenase 2–Mediated Mammary Hyperplasia

¹ Center for Vascular Biology, Department of Cell Biology, University of Connecticut Health Center, Farmington, Connecticut; ² Division of Nephrology and Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee; and ³ Department of Biological Chemistry, University of California, Los Angeles, California

Requests for reprints: Timothy Hla, Center for Vascular Biology, Department of Cell Biology, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030-3501. Phone: 860-679-4128; Fax: 860-679-1269; E-mail: hla{at}nso2.uchc.edu.

Expression of cyclooxygenase 2 (COX-2) in breast cancer correlates with poor prognosis, and COX-2 enzyme inhibitors reduce breast cancer incidence in humans. We recently showed that COX-2 overexpression in the mammary gland of transgenic mice induced mammary cancer. Because prostaglandin E₂ (PGE₂) is the major eicosanoid and because the EP2 subtype of the PGE₂ receptor is highly expressed in the mammary tumors, we tested if this G protein–coupled receptor is required for tumorigenesis. We crossed the MMTV-COX-2 transgenic mice with Ep2^–/– mice and studied tumor development in bigenic mice. Lack of EP2 receptor strongly suppressed COX-2–induced effects such as precocious development of the mammary gland in virgins and the development of mammary hyperplasia in multiparous female mice. Interestingly, the expression of amphiregulin, a potent mammary epithelial cell growth factor was down regulated in mammary glands of Ep2^–/– mice. Total cyclic AMP (cAMP) levels were reduced in Ep2^–/– mammary glands suggesting that PGE₂ signaling via the EP2 receptor activates the G_s/cAMP/protein kinase A pathway. In mammary tumor cell lines, expression of the EP2 receptor followed by treatment with CAY10399 an EP2-specific agonist, strongly induced amphiregulin mRNA levels in a protein kinase A–dependent manner. These data suggest that PGE₂ signaling via the EP2 receptor in mammary epithelial cells regulate mammary gland hyperplasia by the cAMP-dependent induction of amphiregulin. Inhibition of the EP2 pathway in the mammary gland may be a novel approach in the prevention and/or treatment of mammary cancer.

This article has been cited by other articles:

				K.-S. Chun, H.-C. Lao, C. S. Trempus, M. Okada, and R. Langenbach The prostaglandin receptor EP2 activates multiple signaling pathways and {beta}-arrestin1 complex formation during mouse skin papilloma development Carcinogenesis, September 1, 2009; 30(9): 1620 - 1627. [Abstract] [Full Text] [PDF]

				S. J. Baek, M. F. McEntee, and A. M. Legendre REVIEW PAPER: Cancer Chemopreventive Compounds and Canine Cancer Vet. Pathol., July 1, 2009; 46(4): 576 - 588. [Abstract] [Full Text] [PDF]

				T. Murata, M. I. Lin, K. Aritake, S. Matsumoto, S. Narumiya, H. Ozaki, Y. Urade, M. Hori, and W. C. Sessa Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo PNAS, December 16, 2008; 105(50): 20009 - 20014. [Abstract] [Full Text] [PDF]

				J. Frasor, A. E. Weaver, M. Pradhan, and K. Mehta Synergistic Up-Regulation of Prostaglandin E Synthase Expression in Breast Cancer Cells by 17{beta}-Estradiol and Proinflammatory Cytokines Endocrinology, December 1, 2008; 149(12): 6272 - 6279. [Abstract] [Full Text] [PDF]

				A.M. Patwardhan, J. Vela, J. Farugia, K. Vela, and K.M. Hargreaves Trigeminal Nociceptors Express Prostaglandin Receptors Journal of Dental Research, March 1, 2008; 87(3): 262 - 266. [Abstract] [Full Text] [PDF]

				K. Subbaramaiah, C. Hudis, S.-H. Chang, T. Hla, and A. J. Dannenberg EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE J. Biol. Chem., February 8, 2008; 283(6): 3433 - 3444. [Abstract] [Full Text] [PDF]

				K. M. Ansari, Y. M. Sung, G. He, and S. M. Fischer Prostaglandin receptor EP2 is responsible for cyclooxygenase-2 induction by prostaglandin E2 in mouse skin Carcinogenesis, October 1, 2007; 28(10): 2063 - 2068. [Abstract] [Full Text] [PDF]

				K. Meisdalen, O. F. Dajani, T. Christoffersen, and D. Sandnes Prostaglandins Enhance Epidermal Growth Factor-Induced DNA Synthesis in Hepatocytes by Stimulation of E Prostanoid 3 and F Prostanoid Receptors J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1044 - 1050. [Abstract] [Full Text] [PDF]

				K. J. Sales, S. C. Boddy, A. R. W. Williams, R. A. Anderson, and H. N. Jabbour F-Prostanoid Receptor Regulation of Fibroblast Growth Factor 2 Signaling in Endometrial Adenocarcinoma Cells Endocrinology, August 1, 2007; 148(8): 3635 - 3644. [Abstract] [Full Text] [PDF]

				Y. Sugimoto and S. Narumiya Prostaglandin E Receptors J. Biol. Chem., April 20, 2007; 282(16): 11613 - 11617. [Abstract] [Full Text] [PDF]

				J. N. McDougal, C. M. Garrett, C. M. Amato, and S. J. Berberich Effects of Brief Cutaneous JP-8 Jet Fuel Exposures on Time Course of Gene Expression in the Epidermis Toxicol. Sci., February 1, 2007; 95(2): 495 - 510. [Abstract] [Full Text] [PDF]

				A. M. Fulton, X. Ma, and N. Kundu Targeting Prostaglandin E EP Receptors to Inhibit Metastasis. Cancer Res., October 15, 2006; 66(20): 9794 - 9797. [Abstract] [Full Text] [PDF]

				G. D. Basu, T. L. Tinder, J. M. Bradley, T. Tu, C. L. Hattrup, B. A. Pockaj, and P. Mukherjee Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO J. Immunol., August 15, 2006; 177(4): 2391 - 2402. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				G. K. Yiu and A. Toker NFAT Induces Breast Cancer Cell Invasion by Promoting the Induction of Cyclooxygenase-2 J. Biol. Chem., May 5, 2006; 281(18): 12210 - 12217. [Abstract] [Full Text] [PDF]

				B. Rocca Targeting PGE2 Receptor Subtypes Rather Than Cyclooxygenases: A Bridge Over Troubled Water? Mol. Interv., April 1, 2006; 6(2): 68 - 73. [Abstract] [Full Text] [PDF]

				X. Ma, N. Kundu, S. Rifat, T. Walser, and A. M. Fulton Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer Metastasis. Cancer Res., March 15, 2006; 66(6): 2923 - 2927. [Abstract] [Full Text] [PDF]

				J. Shao, G. G. Sheng, R. C. Mifflin, D. W. Powell, and H. Sheng Roles of Myofibroblasts in Prostaglandin E2-Stimulated Intestinal Epithelial Proliferation and Angiogenesis Cancer Res., January 15, 2006; 66(2): 846 - 855. [Abstract] [Full Text] [PDF]

				M. F. Bouchard, H. Taniguchi, and R. S. Viger Protein Kinase A-Dependent Synergism between GATA Factors and the Nuclear Receptor, Liver Receptor Homolog-1, Regulates Human Aromatase (CYP19) PII Promoter Activity in Breast Cancer Cells Endocrinology, November 1, 2005; 146(11): 4905 - 4916. [Abstract] [Full Text] [PDF]